PATENT

Bottcher 5/16/05

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TRADA Phrcant: J. Henslee & P. N. Friedman

Serial No.: 10/816, 326

Filed: April 1, 2004

For: REAGENTS AND METHODS USEFUL FOR DETECTING

DISEASES OF THE BREAST

Examiner: (not assigned)

Group Art Unit: 1645

Case No.: 5972.US.D3

CERTIFICATE OF MAILING (37 CFR 1.8 (a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Mail Stop Amendment Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450, on:

Date of Deposit: May / (2), 2005

TRANSMITTAL LETTER

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed herewith is an Information Disclosure Statement for J. Henslee & P. N. Friedman, for REAGENTS AND METHODS USEFUL FOR DETECTING DISEASES OF THE BREAST, the specification of which was filed on April 1, 2004, and received Serial No. 10/816, 326.

Also enclosed are:

Form PTO 1449 (in duplicate)

Return-receipt postcard

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR 1.16, as well as any patent application processing fees under 37 CFR 1.17 associated with this communication for which full payment has not been tendered, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.

Respectfully submitted, J. Henslee & P. N. Friedman

ABBOTT LABORATORIES

Customer Number: 23492 Telephone: (847) 935-1729 Facsimile: (847) 938-2623 Cheryl L. Becker

Registration No. 35,441 Attorney for Applicants

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: J. Henslee & P. N. Friedman

Serial No.: 10/816, 326

Filed: April 1, 2004

For: REAGENTS AND METHODS
USEFUL FOR DETECTING
DISEASES OF THE BREAST

Examiner: (not assigned)

Group Art Unit: 1645

Case No.: 5972.US.D3

CERTIFICATE OF MAILING (37 CFR 1.8 (a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

mail in an envelope addressed to the:

Mail Stop Amendment Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450, on:

Date of Deposit: May 16, 2005

Kathleen Boettcher 5/16/03
Kathleen Boettcher Date

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits under 37 CFR § 1.97(b).

Applicants submit herewith Form PTO 1449 listing the references cited in this Information Disclosure Statement. Applicants respectfully request that the Examiner (1) initial each reference listed on the enclosed Form PTO 1449 indicating that the Examiner has considered and made those references of record in this application and (2) return a copy of the initialed Form PTO 1449 to Applicants. Copies of the cited references have been previously submitted in U.S. Patent Application Serial No. 09/975,502, filed October 11, 2001. The aforementioned earlier application is relied on for an earlier, patent application filing date under 35 U.S.C. 120.

No charge is required for the submission of this Information Disclosure Statement under 37 C.F.R. § 1.97 (b). The Commissioner is hereby authorized to charge any

additional filing fees required under 37 C.F.R. § 1.17 concerning this transmission, or to credit any overpayment to Deposit Account No. 01-0025.

Respectfully submitted, J. Henslee & P. N. Friedman

ABBOTT LABORATORIES

Customer Number: 23492 Telephone: (847) 935-1729 Facsimile: (847) 938-2623

Cheryl L. Becker

Registration No. 35,441 Attorney for Applicants DATE: May 16, 2005

SHEET 1 of 3

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

5973.US.D3

SERIAL NO.

ATTY. DOCKET NO.

APPLICANT

J. Henslee & P. N. Friedman

FILING DATE

GROUP

10/816,326

April 1, 2004

1645

(Use several sheets if necessary)

MAY 1 8 2005

U.S.PATENT DOCUMENTS

EXAMINER			ISSUE			SUB	FILING
INITIAL		PATENT NUMBER	DATE	PATENTEE	CLASS	CLASS	DATE
	A1	5,668,267	09/16/1997	Watson, et al.			
	A2	4,816,567	03/28/1989	Cabilly, et al.			
	A3	4,946,778	08/07/1990	Ladner, et al.			
	A4	5,254,458	10/19/1993	Mimms			
	A5	2002/0009738	01-2002	Houghton, et al.			
	A6	6,379671	04/30/2002	Colpitts			
	A7	2003/0059432	03/2003	Dillon and Fanger			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC- ATION	COUNTRY OR		SUB	TRA LAT	
			DATE	PATENT OFFICE	CLASS	CLASS	YES	NO
В	1	97/34997	25 Sep 97	PCT				
B	2	2276169	21 Sep 94	GB				
B	3	84/03564	13 Sep 84	EPO				
B	4	0473065	04 Mar 92	EPO				
В	5	0326100	11 Sep 96	EPO				
B	6	0406473	20 Sep 95	EPO		-		
. B	7	0273115	07 Sep 94	EPO				
В	8	0425633	27 Jul 94	EPO				
_ B	9	0424634	14 Jun 95	EPO				
. B	10	95/20681	03 Aug 95	PCT				
В	11	92/01936	06 Feb 92	PCT				
B	12	98/21331	05-1998	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	C1	G.N. Hortobagyi, et al., <u>CA Cancer J Clin</u> 45:199-226 (1995)
	C2	J.R. Harris, et al. Cancer: Principles and Practice of Oncology, Fourth Edition,
		1264-1332, Philadelphia, PA: J/B. Lippincott Co. (1993)
	C3	C.J. Wright, et al., <u>Lancet</u> 346:29-32 (1995)
	C4	M.K. Schwartz, Cancer: Principles and Practice of Oncology, Vo.1, Fourth
		Edition, pp. 531-542, Philadelphia, PA: J/B Lippincott Co. (1993)
	C5	K. Pantel, et al., Onkologie 18:394-401 (1995)
	C6	G.E. Hanks, et al, Cancer: Principles and Practice of Oncology, Vol. 1, Fourth
		Edition, pp. 1073-1113, Philadelphia, PA: JB Lippincott Co. (1993)
	C7	E.R. Frykberg, et al., <u>Cancer</u> 74:350-361 (1994)
EXAMINER		DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE

PATENT AND TRADEMARK OFFICE ATTY. DOCKET NO.

SERIAL NO. 10/816,326

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

J. Henslee & P. N. Friedman

FILING DATE

GROUP

(Use several sheets if necessary)

April 1, 2004

5973.US.D3

APPLICANT

1645

(37 CFR 1.98 (b))

(Modified)

	C8	THER DOCUMENTS (Including Author, Title, Date, Place of Publication) T.E. Creighton, et al. Proteins: Structures and Molecular properties, Second
		Edition, pp. 78-102, New York, NY:WH Freeman and Co. (1993)
	C9	L. Miele, et al., <u>J. Endocrinol. Invest.</u> 17:679-692 (1992)
	C10	R.Bally, et al., J. Mol Biology 206:153-170 (1989)
	C11	I. Morize, et al., <u>J. Mol Biol</u> , 194:725-739 (1987)
	C12	T.C. Umland, et al., Nature Structural Biology, 1:538-545 (1994)
	C13	Grunewald, K., et al., Lab. Invest., Mammaglobin Gene Expression: A Superio
		Marker fo Brast Cancer Cells in Peripheral Blood in Comparison to Epidermal-
		Growth-Factor Receptro and Cytokeratin-19, 80: 1071-1077, (2000)
	C14	T.C. Umland, et al., <u>J. Mol. Biol.</u> 224:441-448 (1992)
	C15	O.A. Duffort, et al., Molecular Immunology 28:301-309 (1991)
	C16	K. Leitermann, et al., J. Of Allergy and Clinical Immunology, 74:147-153 (1991)
	C17	M. Parker et al., Nature, 298:92-94 (1982)
	C18	J.P. Morgenstern, et al., PNAS, 88:9690-9694 (1991)
	C19	M.A. Watson, et al., Cancer Research, 56:860-865 (1996)
	C20	M.A. Watson, et al., Oncogene, 16: 817-824 (1998)
	C21	O. Zach, et al., Detection of Circulating Mammary Carcinoma Cells in the
		Peripheral Blood of Breast Cancer Patients Via a Nested Reverse
		Transcriptase Polymerase Chain Reaction Assay for Mammaglobin mRNA J.
		Clin. Oncol, 17:2015-2019 (1999)
	C22	H.J. Kahn, et al., RT-PCR amplification of CK19 mRNA in the Blood of Breast
		Cancer Patients: Correlation with Established Prognostic Parameters Breast
		<u>Cancer Res. Treat</u> , 60: 143-151 (2000)
	C23	Isao Miysahiro, et al., Molecular Strategy for Detecting Metastatic Cancers with
		Use of Multiple Tumor-specific MAGE-A Genes, Clinical Chemistry, 47: 3 505-
		512 (2001)
	C24	Smith & Waterman, Advances in Applied Mathematics 2:482-442 (1981)
	C25	Dayhoff, Atlas of Protein Sequences and Structure, M.O. Dayhoff, ed. 5 Suppl.
		3:353-358
	C26	Gribskov, Nucl. Acids Res., 14(6): 6745-6763 (1986)
	C27	F. Wold, Posttraslational Protein Modifications: Perspectives and Prospects,
-		pp. 1-12, B.C. Johnson, Ed., Academic Press, New York (1983)
	C28	Seifter, et al., Analysis for Protein Modification and Non Protein Cofactors,
		Meth. Enzymol., 182: 626-464 (1990)
XAMINER		DATE CONSIDERED

not considered. Include copy of this form with next communication to applicant.

DATE: May <u>/6</u>, 2005

SHEET 3 of 3

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.	
	5973.US.D3	10/816,326	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT J. Henslee & P. N. Friedman		
(Use several sheets if necessary)	FILING DATE	GROUP	
(37 CFR 1.98 (b))	April 1, 2004	1645	

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	C20	Detter et al. Detain Coulty de Deuts La LA LIG LA
	C29	Rattan, et al., <u>Protein Synthesis: Posttranslational Modifications and Aging, Ann N.Y. Acad Sci.</u> , 663: 48-62 (1992)
	C30	Inbar, et al., Proc. Natl. Acad. Sci. USA, 69: 2659-2662 (1972)
· .	C31	Winter, et al., Nature, 349: 293-299 (1991)
	C32	Ehrlich, et al., <u>Biochem</u> , 19: 4091-4096 (1980)
	C33	Huston, et al., Proc. Natl. Acad. Sci. USA 85: 5879-5883 (1988)
	C34	Riechmann, et al., <u>Nature</u> , 332: 323-327 (1988)
	C35	Verhoeyan, et al., <u>Nature</u> , 332: 323-327 (1988)
	C36	J. Hodgson, Bio/Technology 9:19-21 (1991)
	C37	
	C38	S. Braxton, et al., <u>Biochemistry</u> , 31:7796-7801 (1992)
, , , .	C39	S.B.P. Athauda, et al., <u>J. Biochem</u> (Tokyo) 113 (6):742-746 (1993)
		Gluzman, Cell, 23:175 (1981)
	C40	Price, et al., J. Biol. Chem 244:917 (1969)
	C41	Kohler and Milstein, Nature 256:495-497 (1975)
	C42	Kozbor, et al., Immun. Today, 4:72 (1983)
	C43	Cole, et al., Monoclonal Antibodies and Cancer Therapy, Alan r. Liss, Inc., New York, NY pp. 77-96 (1985)
	C44	Sumerdon, et al., Nucl. Med. Biol, 17:247-254 (1990)
	C45	Griffin, et al., <u>J. Clin Onc</u> , 9:631-640 (1991)
	C46	R.B. Lauffer, Magnetic Resonance in Medicine, 22:339-342 (1991)
	C47	Garnett and Baldwin, Cancer Research 46:2407-2412 (1986)
	C48	Pastan, et al., Cell 47:641-648 (1986)
	C49	Goodwin and Meares, Cancer Supplement, 80:2675-2680 (1977)
- 712	C50	Mimms, et al., Virology 176:604-619 (1990)
	C51	V. Van Heyningen Methods in Enzymology, Vol. 121, p. 472 (1986)
	C52	X. Qiu, et al., Journal of Immunology, Vol. 156, p. 3350 (1996)
	C53	F.L. Graham, et al., J. Gen. Vir., 36:59-72 (1977)
	C54	S.R. Kain, et al., Biotechniques, 17:982 (1994)
EXAMINER	·	DATE CONSIDERED
		tion considered. Draw line through citation if not in conformance and
not consider	ed. Includ	de copy of this form with next communication to applicant.

(Form PTO-1449)